Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial

ACTA MEDICA INDONESIANA · Vol. 55 No. 4 (2024)

ISSN
2338-2732, 0125-9326
Terbit
2024-01-12
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 176 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Institut Agama Islam Negeri Bone
  • Universitas Teknologi Sumbawa
  • Universitas Teuku Umar
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Mediarty SyahrirAfiliasi tidak diketahui2
Aisyah WirdahAfiliasi tidak diketahui2
Norman DjamaludinAfiliasi tidak diketahui2
Simon SalimAfiliasi tidak diketahui2
Andhika RachmanAfiliasi tidak diketahui2
Ida KusriniAfiliasi tidak diketahui1
Alwi ShahabAfiliasi tidak diketahui1
Irsan SalehAfiliasi tidak diketahui1
Yunni DiansariAfiliasi tidak diketahui1
Mita AndrianiAfiliasi tidak diketahui1
Muhammad YaminInstitut Agama Islam Negeri Bone1
Lusiani RusdiAfiliasi tidak diketahui1
Muhammad Syahrir AziziAfiliasi tidak diketahui1
Anneira Amanda PutriAfiliasi tidak diketahui1
Ali Zainal AbidinAfiliasi tidak diketahui1
Krisna MurtiAfiliasi tidak diketahui1
Lisnawati LisnawatiUniversitas Teknologi Sumbawa1
Joedo PrihartonoAfiliasi tidak diketahui1
Jeffry Beta TenggaraAfiliasi tidak diketahui1
Sonar Soni PanigoroAfiliasi tidak diketahui1
Didik Setyo HeriyantoAfiliasi tidak diketahui1
Ricci StevenAfiliasi tidak diketahui1
Kevin TandartoAfiliasi tidak diketahui1
Samuel JuanputraAfiliasi tidak diketahui1
Hayatun NufusUniversitas Teuku Umar1
Lugyanti SukrismanAfiliasi tidak diketahui1
Rudy HidayatAfiliasi tidak diketahui1
Evy YunihastutiAfiliasi tidak diketahui1
Eka GinanjarAfiliasi tidak diketahui1
Sally Aman NasutionAfiliasi tidak diketahui1
Ceva Wicaksono PitoyoAfiliasi tidak diketahui1
Adityo SusiloAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and  hs-CRP in Patients Receiving Capecitabine: A Randomized Trial</dc:title>
	<dc:creator>Andayani, Yenny Dian</dc:creator>
	<dc:creator>Saleh, Mgs. Irsan</dc:creator>
	<dc:creator>Sudoyo, Aru Wisaksono</dc:creator>
	<dc:creator>Ali, Zulkhair</dc:creator>
	<dc:creator>Legiran, Legiran</dc:creator>
	<dc:creator>Partan, Radiyati Umi</dc:creator>
	<dc:creator>Yuristo, Eddy</dc:creator>
	<dc:creator>Lubis, Fadhyl Zuhry</dc:creator>
	<dc:subject xml:lang="en-US">Hand Foot Syndrome</dc:subject>
	<dc:subject xml:lang="en-US">C-Reactive Protein</dc:subject>
	<dc:subject xml:lang="en-US">Extra Virgin Olive Oil</dc:subject>
	<dc:subject xml:lang="en-US">Capecitabine</dc:subject>
	<dc:description xml:lang="en-US">Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2024-01-12</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2534</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 4 (2023): Acta Medica Indonesiana; 396</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2534/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Yenny Dian Andayani, Mgs. Irsan Saleh, Aru Wisaksono Sudoyo, Zulkhair Ali, Legiran Legiran, Radiyati Umi Partan, Eddy Yuristo, Fadhyl Zuhry Lubis</dc:rights>
</oai_dc:dc>